Nikethamide

Central respiratory depression is a common critical complication in clinical anesthesia, intensive care and first-aid scenarios, which may lead to irreversible brain damage and even death if not intervened in time. As a classic respiratory stimulant API, nikethamide belongs to the category of central nervous system stimulants. It can selectively excite the respiratory center in the medulla oblongata, and can also act on the chemoreceptors of the carotid body and aortic body to reflexively excite the respiratory center. By increasing the sensitivity of the respiratory center to carbon dioxide, it deepens and accelerates respiration, and has a weak excitatory effect on the vasomotor center. It is mainly used clinically for central respiratory depression and respiratory depression caused by various reasons, and is a standing first-aid drug in emergency departments, anesthesiology departments and other departments, suitable for all kinds of patients with insufficient ventilation caused by suppressed central function.

At present, the domestic nikethamide market is in a mature and stable development stage, and there is no publicly verifiable authoritative market size and growth rate data. In terms of the competitive landscape, this variety has been out of patent for many years, with a large number of domestic generic enterprises, and the price is in a low range. Due to its rigid demand attribute as a first-aid drug, the clinical usage volume has remained stable throughout the year, the market supply is sufficient, and there is no obvious supply-demand gap.

The original research enterprise of nikethamide is Novartis, with the original brand name Coramine, and the core compound patent expired as early as 1960. At present, the main dosage form of nikethamide marketed in China is nikethamide injection, with common specifications of 1.5ml:0.375g and 2ml:0.5g. This product has been included in the *Catalogue of Reference Preparations for Chemical Drugs* issued by the National Medical Products Administration. A number of domestic enterprises have completed the CDE registration of nikethamide API, and dozens of nikethamide injection varieties have been approved for marketing. (Data as of June 2025, please refer to the official website of CDE for the latest information)

CATO can provide a full set of impurity reference standards for nikethamide API. Most of the products are available in stock. Orders for in-stock products placed before 16:00 can be shipped on the same day. All reference standards comply with the compliance requirements of multiple regulations such as Chinese Pharmacopoeia and FDA, and fully meet the needs of API enterprises in various scenarios such as quality research, consistency evaluation and daily production quality control.